The Evidence
What do the experts say about CBD for arthritis?
TL;DR — What the Evidence Shows
Major medical groups do not recommend CBD for arthritis. The Arthritis Foundation says more research is needed. The ACP says known harms may outweigh small benefits.
How do the major organizations compare?
| Organization | Position on CBD for Arthritis | Year |
|---|---|---|
| American College of Rheumatology (ACR) | Conditionally recommends against CBD for osteoarthritis management | 2019 |
| American College of Physicians (ACP) | "Known harms may outweigh potentially small degree of benefit" | 2025 |
| Arthritis Foundation | Acknowledges patient interest; calls for more research; does not recommend | 2019 |
| U.S. Food and Drug Administration (FDA) | Has not approved CBD for arthritis or any pain condition | Current |
| World Health Organization (WHO) | No recommendation for CBD for arthritis pain | Current |
What does each organization say?
American College of Rheumatology (ACR)
The ACR's 2019 guideline for hand, hip, and knee osteoarthritis conditionally recommends against using CBD for osteoarthritis. This means the organization found insufficient evidence to support its use and some reasons to be cautious.
The ACR is the primary professional organization for rheumatologists in the United States. Their guidelines are developed by panels of specialists who review available evidence systematically.
American College of Physicians (ACP) — 2025
The ACP published best practice advice on cannabis and cannabinoids for chronic noncancer pain in 2025. Their assessment of CBD was cautious:
"Known harms may outweigh potentially small degree of benefit."
The ACP noted that the overall evidence for CBD alone (as opposed to THC-containing products) showed mostly negative results for pain. They emphasized drug interaction risks and the lack of product regulation.
Arthritis Foundation
The Arthritis Foundation has taken a measured position. They surveyed 2,600 people with arthritis in 2019 and found high rates of self-reported benefit from CBD use. Human Survey
However, their official position calls for more research rather than recommending CBD. They do not endorse specific CBD products. They have advocated for better regulation and more clinical trials.
The Foundation acknowledges that many people with arthritis use CBD and have reported benefit, while noting that controlled studies have not confirmed these reports.
U.S. Food and Drug Administration (FDA)
The FDA has approved one CBD product — Epidiolex — for specific forms of epilepsy. It has not approved CBD for arthritis, pain, or any other condition.
The FDA has issued warning letters to CBD companies making unapproved health claims. The agency has also noted that CBD products are not evaluated for safety, effectiveness, or quality before they are sold to consumers.
In 2025, the FDA published results of a clinical trial in healthy adults showing that CBD at consumer-relevant doses (253-550 mg per day) caused liver enzyme elevations in about 6 out of 100 participants. Human Trial
World Health Organization (WHO)
The WHO has reviewed CBD's safety profile and determined it is generally well tolerated with a good safety profile at low doses. However, the WHO has not issued a recommendation for CBD as a treatment for arthritis pain.
The WHO's December 2023 guideline on low back pain conditionally recommended acupuncture but did not include CBD or cannabis products among its recommended treatments.
Why the gap between expert opinion and public use?
Surveys consistently show that many people with arthritis use CBD and report benefit. The Arthritis Foundation survey found that roughly 65 to 80 out of 100 respondents said CBD improved their symptoms. Human Survey
Medical organizations base their recommendations on controlled trials, where participants are randomly assigned to CBD or placebo and neither the participant nor the researcher knows which they received. In these controlled conditions, CBD has not shown a significant benefit over placebo for arthritis pain. Human Trial
Several factors may explain the gap:
- Placebo and expectation effects. Pain is strongly influenced by what a person expects to happen. Media attention about cannabis therapies has been linked to higher placebo response rates in pain trials (Gedin 2022).
- No control group in surveys. Without a comparison to people taking placebo, surveys cannot separate the effect of CBD from other factors like natural fluctuation in symptoms, relaxation routines, or the belief that a treatment is helping.
- Product differences. Survey respondents may use products that contain THC or other compounds alongside CBD. Controlled trials typically test pure CBD.
- Selective reporting. People who feel CBD helped them may be more likely to respond to a survey about it. People who tried it and found no benefit may be less likely to participate.
None of this means reported benefit is not real to the person experiencing it. But it does explain why medical organizations, which rely on controlled evidence, have not recommended CBD for arthritis.
CBD interacts with many common medications
- The ACP specifically flagged drug interaction risks in their 2025 guidance
- Blood thinners (warfarin), statins, and immunosuppressants are among affected medications
- The ACP, ACR, and Arthritis Foundation all advise discussing CBD with a healthcare provider before use
Based on cited sources. This is not personalized medical advice — discuss with your healthcare provider.
Full drug interaction guide, medication checker, and pharmacist discussion checklist.
Key sources cited on this page
Page last reviewed: March 2026 · Authored by Claude (Anthropic AI) · Research methodology